• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Opus Genetics Inc.

    1/22/26 5:03:23 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IRD alert in real time by email
    S-8 1 ef20063513_s8.htm S-8
    As filed with the Securities and Exchange Commission on January 22, 2026
    Registration No. 333-


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

    Opus Genetics, Inc.
    (Exact name of registrant as specified in its charter)

    Delaware
     
    11-3516358
    (State or other jurisdiction of incorporation or organization)
     
    (I.R.S. Employer Identification Number.)

    8 Davis Drive
    Durham, NC
     
    27713
    (Address of principal executive offices)
     
    (Zip code)

    Ocuphire Pharma, Inc. 2020 Equity Incentive Plan
    (Full title of the plan)
    Dr. George Magrath
    Chief Executive Officer
    Opus Genetics, Inc.
    8 Davis Drive
    Durham, NC 27713
    (984) 884-6030
    (Name, address, and telephone number, including area code, of agent for service)

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer ☐
    Accelerated filer ☐
    Non-accelerated filer ☒
    Smaller reporting company ☒
     
    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    EXPLANATORY NOTE

    INFORMATION REQUIRED PURSUANT TO GENERAL INSTRUCTION E TO FORM S-8

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by Opus Genetics, Inc. (the “Registrant”) relating to 3,494,725 shares of its common stock, par value $0.0001 per share (the “Common Stock”), to be issued pursuant to the Ocuphire Pharma, Inc. 2020 Equity Incentive Plan (the “Plan”). This Registration Statement on Form S-8 hereby incorporates by reference the contents of the Registrant's prior Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on November 9, 2020 (Registration No. 333-249978), March 31, 2021 (Registration No. 333-254923), April 5, 2022 (Registration No. 333-264139), April 5, 2023 (Registration No. 333-271150), January 11, 2024 (Registration No. 333-276471) and September 26, 2025 (Registration No. 333-290551) relating to shares of Common Stock issuable under the Plan (the “Prior Registration Statements”). The Prior Registration Statements are currently effective. This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E of Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    All information required by Part I to be contained in the prospectus is omitted from this Registration Statement in accordance with the explanatory note to Part I of Form S-8 and Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”). Documents containing the information required by Part I of the Registration Statement will be sent or given to Plan participants as specified by Rule 428(b)(1) under the Securities Act.

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3.
    Incorporation of Documents By Reference.

    The following documents filed with the Commission by the Registrant are hereby incorporated by reference in this Registration Statement:

    (a)
    the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 31, 2025 (the “2024 Annual Report”);

    (b)
    the Registrant’s Quarterly Reports on Form 10-Q, filed with the Commission on May 15, 2025, August 13, 2025 and November 12, 2025;

    (c)
    the Registrant’s Current Reports on Form 8-K, filed with the Commission on January 7, 2025, January 14, 2025, January 23, 2025, January 24, 2025, March 4, 2025, March 20, 2025, March 24, 2025, April 4, 2025, May 1, 2025, June 20, 2025, June 25, 2025, June 26, 2025, July 23, 2025, August 25, 2025, September 2, 2025, September 30, 2025, November 6, 2025, November 6, 2025, and December 19, 2025; and

    (d)
    the description of the Registrant’s Common Stock contained in the Registrant’s Form 8-A (File No. 001-34079), as filed with the Commission pursuant to Sections 12(b) and 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on June 7, 2019, including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.12 to the 2024 Annual Report.

    All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the respective dates of filing of such documents (such documents, and the documents enumerated above, being hereinafter referred to as “Incorporated Documents”).


    Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Notwithstanding the foregoing, unless specifically stated to the contrary, none of the information disclosed by the Registrant under Items 2.02 or 7.01 of any current report on Form 8-K, including the related exhibits under Item 9.01, that the Registrant may from time to time furnish to the Commission will be incorporated by reference into, or otherwise included in, this Registration Statement.


    Item 8.1
    Exhibits.

    Exhibit
    Number
    Description
    4.1
    Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q, filed with the Commission on August 13, 2024).
       
    4.2
    Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the Commission on October 22, 2024).
       
    4.3
    Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on March 20, 2025).
       
    4.4
    Ocuphire Pharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Annex D to the Registrant’s Registration Statement on Form S-4, filed with the Commission on July 6, 2020).
       
    5.1*
    Opinion of Sidley Austin LLP.
       
    23.1*
    Consent of Ernst & Young LLP.
       
    23.2*
    Consent of Sidley Austin LLP (included in Exhibit 5.1).
       
    24.1*
    Power of Attorney (included after the signature of the Registrant contained on Signature Page of this Registration Statement).
       
    107*
    Filing Fee Table.

    * Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina, on January 22, 2026.

     
    OPUS GENETICS, INC.
       
     
    By:
    /s/ Dr. George Magrath
     
    Name:
    Dr. George Magrath
     
    Title:
    Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Dr. George Magrath and Robert Gagnon as his or her true and lawful attorneys-in-fact and agents with full power of substitution, severally, for him in any and all capacities, to sign the Registration Statement on Form S-8 of Opus Genetics, Inc., and any or all amendments (including post-effective amendments thereto), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

    SIGNATURE
     
    TITLE
     
    DATE
             
    /s/ Dr. George Magrath
           
    Dr. George Magrath
     
    Chief Executive Officer & Director
    (Principal Executive Officer)
     
    January 22, 2026
    /s/ Robert Gagnon
           
    Robert Gagnon
     
    Chief Financial Officer
    (Principal Financial Officer and Principal Accounting Officer)
     
    January 22, 2026
             
    /s/ Cam Gallagher
           
    Cam Gallagher
     
    Chair of the Board
     
    January 22, 2026
             
    /s/ Sean Ainsworth
           
    Sean Ainsworth
     
    Director
     
    January 22, 2026
             
    /s/ Dr. Jean Bennett
           
    Dr. Jean Bennett
     
    Director
     
    January 22, 2026
             
    /s/ Susan K. Benton
           
    Susan K. Benton
     
    Director
     
    January 22, 2026
             
    /s/ Dr. Adrienne Graves
           
    Dr. Adrienne Graves
     
    Director
     
    January 22, 2026
             
    /s/ Dr. James S. Manuso
           
    Dr. James S. Manuso
     
    Director
     
    January 22, 2026
             
    /s/ Richard J. Rodgers
           
    Richard J. Rodgers
     
    Director
     
    January 22, 2026
             
    /s/ Dr. Benjamin R. Yerxa
           
    Dr. Benjamin R. Yerxa
     
    President and Director
     
    January 22, 2026



    Get the next $IRD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRD

    DatePrice TargetRatingAnalyst
    3/30/2026$15.00Overweight
    Cantor Fitzgerald
    3/16/2026$10.00Outperform
    Oppenheimer
    1/20/2026$7.00Buy
    BTIG Research
    12/10/2025$9.00Buy
    B. Riley Securities
    11/25/2025$7.00Overweight
    Piper Sandler
    10/29/2025$8.00Outperform
    Wedbush
    10/16/2025$9.00Buy
    Chardan Capital Markets
    4/11/2025$6.00Buy
    Craig Hallum
    More analyst ratings

    $IRD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gallagher Cam bought $323,693 worth of shares (164,000 units at $1.97) and was granted 33,000 shares, increasing direct ownership by 6% to 1,924,430 units (SEC Form 4)

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    12/31/25 4:33:33 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Magrath George bought $97,600 worth of shares (100,000 units at $0.98), increasing direct ownership by 20% to 599,150 units (SEC Form 4)

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    12/30/24 4:26:20 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Yerxa Benjamin R bought $9,834 worth of shares (10,000 units at $0.98), increasing direct ownership by 3% to 342,800 units (SEC Form 4)

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    11/25/24 4:18:07 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Opus Genetics with a new price target

    Cantor Fitzgerald initiated coverage of Opus Genetics with a rating of Overweight and set a new price target of $15.00

    3/30/26 8:19:42 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Opus Genetics with a new price target

    Oppenheimer initiated coverage of Opus Genetics with a rating of Outperform and set a new price target of $10.00

    3/16/26 8:42:37 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Opus Genetics with a new price target

    BTIG Research initiated coverage of Opus Genetics with a rating of Buy and set a new price target of $7.00

    1/20/26 9:23:30 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

    RESEARCH TRIANGLE PARK, N.C., March 24, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), is proud to have been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2026 in the Biotech category. This year's list shines a spotlight on businesses that are shaping industry and culture through their innovations. Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 720 honorees across 59 sectors and regions. "We are honored to be recogniz

    3/24/26 7:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

    - Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA's Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus' deep pipeline in rare inherited retinal diseases -- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -- Funding from prominent healthcare investors expected to extend cash runway into 2028 - RESEARCH TRIANGLE PARK, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or

    3/10/26 7:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opus Genetics to Present at Upcoming Investor Conferences in March 2026

    RESEARCH TRIANGLE PARK, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the following investor conferences. Leerink Global Healthcare Conference Date: Tuesday, March 10, 2026Time: 3:00 p.m. ETLocation: Miami, FL Citizens Life Sciences Conference Date: Wednesday, March 11, 2026Time: 2:50 p.m. ETLocation: Miami, FL RBC Capital Markets Global Ophthalmology Conference Date: Wednesday, March 25, 2026Time: 11:45 a.m. ETLoc

    3/3/26 8:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    SEC Filings

    View All

    SEC Form DEF 14A filed by Opus Genetics Inc.

    DEF 14A - Opus Genetics, Inc. (0001228627) (Filer)

    3/23/26 4:06:05 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Opus Genetics Inc.

    S-3 - Opus Genetics, Inc. (0001228627) (Filer)

    3/13/26 4:56:07 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Opus Genetics Inc.

    PRE 14A - Opus Genetics, Inc. (0001228627) (Filer)

    3/12/26 4:58:34 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Schachle Joseph K

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    3/18/26 4:12:35 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Zaremba Rabourn Amy

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    3/18/26 4:11:39 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Magrath George

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    3/18/26 4:10:31 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Leadership Updates

    Live Leadership Updates

    View All

    Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

    RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced the appointment of Rob Gagnon, CPA, MBA, as Chief Financial Officer. Mr. Gagnon is an accomplished biotech executive with more than two decades of financial and operational leadership experience in both public and private companies. He has raised over $2 billion in capital, executed multiple strategic transactions, and held senior roles guiding companies through IPOs, late-stage clinical development, commercial

    9/2/25 8:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Financials

    Live finance-specific insights

    View All

    Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

    - Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA's Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus' deep pipeline in rare inherited retinal diseases -- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -- Funding from prominent healthcare investors expected to extend cash runway into 2028 - RESEARCH TRIANGLE PARK, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or

    3/10/26 7:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

    Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicitiesLasting, durable responses observed out to 18 months in adult participantsExpected FDA Meeting in Q4 2025Management to Host Webcast and Conference Call Today at 8:30 A.M. ET RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced positive three-month data from the pediatric cohort

    9/30/25 7:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

    - Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 -- FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 - - Positive topline results reported from VEGA-3 and LYNX-2 Phase 3 trials with Phentolamine Ophthalmic Solution 0.75% - - OPGx-BEST1 on track to enter Phase 1/2 trial in H2 2025 for the treatment of bestrophin-1 related inherited retinal disease - - Non-dilutive funding from patient advocacy groups secured to advance multiple early-stage gene therapy programs - RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, In

    8/13/25 4:30:00 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Opus Genetics Inc.

    SC 13D - Opus Genetics, Inc. (0001228627) (Subject)

    10/29/24 5:26:27 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care